CeriBell (NASDAQ:CBLL) VP Sells 9,255 Shares

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 9,255 shares of CeriBell stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $24.25, for a total value of $224,433.75. Following the sale, the vice president directly owned 34,144 shares in the company, valued at approximately $827,992. The trade was a 21.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

David Foehr also recently made the following trade(s):

• On Monday, August 24th, David Foehr sold 859 shares of CeriBell stock. The stock was sold at an average price of $23.95, for a total value of $20,573.05.
• On Friday, August 21st, David Foehr sold 993 shares of CeriBell stock. The shares were sold at an average price of $24.02, for a total value of $23,851.86.

CeriBell Stock Performance

Shares of CBLL traded down $0.98 during midday trading on Thursday, hitting $23.43. 220,126 shares of the stock traded hands, compared to its average volume of 327,873. The business’s 50 day moving average price is $21.03 and its two-hundred day moving average price is $19.61. The firm has a market capitalization of $899.24 million, a PE ratio of -13.31 and a beta of 0.95. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.79 and a current ratio of 9.18. CeriBell, Inc. has a 1-year low of $10.85 and a 1-year high of $25.33.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The business had revenue of $28.10 million during the quarter, compared to analyst estimates of $27.28 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. Equities research analysts predict that CeriBell, Inc. will post -1.96 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on CBLL shares. Canaccord Genuity Group lifted their target price on CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Barclays upgraded shares of CeriBell to a “neutral” rating in a report on Tuesday, August 18th. Raymond James Financial restated a “strong-buy” rating and set a $29.00 target price on shares of CeriBell in a report on Thursday, September 3rd. Weiss Ratings cut CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 28th. Finally, BTIG Research lifted their target price on CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $24.40.

Institutional Investors Weigh In On CeriBell

Hedge funds have recently made changes to their positions in the company. BlackRock Inc. purchased a new position in CeriBell during the 2nd quarter worth approximately $37,657,000. Vanguard Group Inc. boosted its position in shares of CeriBell by 11.1% in the third quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company’s stock worth $16,935,000 after buying an additional 147,013 shares during the period. KCM Capital Inc grew its holdings in shares of CeriBell by 40.0% during the first quarter. KCM Capital Inc now owns 1,400,000 shares of the company’s stock valued at $25,662,000 after buying an additional 400,000 shares in the last quarter. Yu Fan grew its holdings in shares of CeriBell by 10.7% during the second quarter. Yu Fan now owns 1,353,166 shares of the company’s stock valued at $25,345,000 after buying an additional 130,964 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in CeriBell by 1,945.9% during the fourth quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock valued at $26,797,000 after buying an additional 1,162,200 shares during the period.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.